Key Takeaways AMGN's Q3 revenues rose 12% to $9.6B, with earnings of$5.64 per share beating expectations.Repatha, Evenity, Prolia and Tezspire all posted strong volume-driven double-digit sales growth.AMGN lifted 2025 guidance after robust product sales and rising biosimilar contributions.Amgen (AMGN) reported third-quarter 2025 adjusted earnings of $5.64 per share, which beat the Zacks Consensus Estimate of$5.00 per share. Earnings rose 1% year over year as higher revenues were partially offset by higher ...